ICU agitation
Conditions
Interventions
Trial Group 1:Remimazolam 0.5mg/kg/h
Trial Group 2:Remimazolam 1mg/kg/h
Trial Group 3:Remimazolam 1.5mg/kg/h
Trial Group 4:Remimazolam 2mg/kg/h
Trial Group 5:Remimazolam 2.5mg/kg/h
Trial Group 6:Remimazolam 3mg/kg/h
Sponsors
Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients aged > 18 and = 8h and < 24h.
Exclusion criteria
Exclusion criteria: 1. Included in this study previously; 2. Pregnant; 3. Lactant; 4. Severe central nervous system disease (massive cerebral infarction/hemorrhage; status epilepticus; severe dementia, etc.); 5. Acute hepatitis; 6. The operation is kidney transplantation; 7. The operation is liver transplantation; 8. The operation is brain surgery (except interventional embolization of the aneurysm); 9. Impossible to follow doctor's order due to brain trauma before the operation; 10. Severe liver disease (Child-Pugh C); 11. Chronic kidney disease (CKD grade 3 above); 12. Myasthenia gravis; 13. Allergic to benzodiazepines or its excipients (lactose/dextrin 40); 14. Unstable angina pectoris or acute myocardial infarction; 15. Left ventricular ejection fraction 15ug/kg/min or epinephrine > 0.2ug/kg/min or norepinephrine > 0.2ug/kg/min) are used to maintain SBP above 90mmHg after sufficient fluid resuscitation; 19. Acute glaucoma; 20. Alcohol or drug withdrawal; 21. Psychopath.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effective dose of remimazolam besylate for sedation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Effects on patients' circulation; | — |
Countries
China
Contacts
Public ContactYou Shang
Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Outcome results
None listed